Kinaset Taps M&A Veterans to Steer Asthma Drug Through High-Stakes Trials

BOSTON, MA – June 30, 2026 – In a move that speaks volumes about its ambitions, clinical-stage biopharmaceutical company Kinaset Therapeutics has appointed two seasoned industry leaders to its board. Daniel G. Welch, a veteran CEO with a history of orchestrating major acquisitions, takes the helm as Chairman, while David Lubner, a finance executive with deep M&A experience, joins as an independent director and Chair of the Audit Committee.

These appointments are not standard procedural shuffles. Coming on the heels of an oversubscribed $103 million Series B financing round, they signal a deliberate and strategic reinforcement of the company’s leadership as it navigates the critical Phase 2b clinical trial for its lead asset, frevecitinib, an inhaled therapy for severe asthma. For a company moving from pilot to production, bringing in leaders known for execution is a clear statement of intent.

A Board Built for the Endgame

The resumes of the new appointees read like a who's who of successful biotechnology exits. Daniel G. Welch is best known for his tenure as CEO of InterMune, where he guided the development and commercialization of the blockbuster drug Esbriet before engineering the company's acquisition by Roche. His experience also includes serving as Chairman and CEO of Triangle Pharmaceuticals until its sale to Gilead Sciences. His board service at companies like Seagen (acquired by Pfizer) and AveXis (acquired by Novartis) further cements his reputation as a leader who knows how to build and monetize value.

"Frevecitinib has the potential to offer a differentiated treatment option for patients with severe inflammatory respiratory disease," Mr. Welch stated. "The company has built meaningful momentum with the initiation of its Phase 2b trial, and I look forward to working closely with the Board and management team to help advance the program and realize its broader potential."

Joining him is David Lubner, whose financial acumen has been central to several high-profile deals. He was the Chief Financial Officer at Ra Pharma during its acquisition by UCB and held the same role at ProScript, where the foundational science for the cancer drug Velcade was developed. His appointment as Audit Committee Chair provides the rigorous financial oversight essential for a well-capitalized company preparing for its next phase of growth.

"Kinaset has assembled an exceptional leadership team, a differentiated clinical program and a strong financial foundation," said Mr. Lubner. "I am excited to join the Board and look forward to helping guide the company through its next state of growth and value creation."

This strategic transition includes the departure of founding Board Chair Thomas B. King, who steps down to pursue a new opportunity. In a statement, CEO Robert Clarke, PhD, praised Mr. King's "instrumental role" in Kinaset's growth. The seamless handover to a chairman of Welch's caliber suggests a well-managed succession designed to escalate, not alter, the company’s trajectory.

"Dan and David join the Board at an exciting and important time for Kinaset," Dr. Clarke said. "Dan has successfully led biotechnology companies through clinical development, commercialization and value-creating strategic transactions, while David brings deep expertise in finance, capital markets, strategic transactions and corporate governance. Together, they add complementary experience that will be invaluable as we advance frevecitinib and position Kinaset for its next phase of clinical and corporate growth."

The High-Stakes Bet on an Inhaled JAK Inhibitor

At the heart of Kinaset's strategy is frevecitinib, an investigational inhaled pan-Janus kinase (JAK) inhibitor. Unlike oral JAK inhibitors that have faced scrutiny for systemic side effects, frevecitinib is designed for localized delivery, aiming to provide potent anti-inflammatory activity directly in the lungs while minimizing exposure to the rest of the body. This approach could offer a superior safety profile, a critical differentiator in treating a chronic condition like asthma.

The company is currently enrolling patients in its Phase 2b PANAIRAMA trial, a dose-ranging study for patients with severe asthma who are not adequately controlled by the current standard of care. The severe asthma market is crowded with effective but highly specific biologics, such as those targeting the IL-5 or IL-4 pathways. While transformative for many, these treatments primarily address patients with Type 2 inflammation, often identified by high eosinophil counts.

Kinaset is betting that frevecitinib's mechanism as a pan-JAK inhibitor—blocking multiple inflammatory cytokine pathways simultaneously—can benefit a much broader patient population. This includes the significant number of severe asthma patients with non-eosinophilic or non-Type 2 inflammation, a group with limited effective treatment options. Success in this population would not just carve out a niche; it would address a major unmet need and unlock a substantial market.

Fueling the Engine for Clinical and Corporate Growth

The advancement of frevecitinib is powered by the $103 million Series B financing completed earlier this year. The round was co-led by prominent new investors RA Capital Management and Forge Life Science Partners, with participation from a syndicate of top-tier life science funds. This robust financial backing provides Kinaset with the necessary runway to see its Phase 2b trial through to completion and prepare for subsequent late-stage development.

The capital infusion and the new board appointments are two sides of the same coin. Investors are not just funding a molecule; they are backing a team they believe can successfully navigate the treacherous path of drug development. The addition of Welch and Lubner provides that assurance, installing a governance framework prepared for the complexities of late-stage trials, potential public market entry, or strategic partnership discussions.

Appointing an independent Audit Committee Chair with Lubner's background is a hallmark of mature corporate governance. It signals to investors and potential partners a commitment to financial transparency and rigorous oversight, building the credibility required for future value-creating events.

A Broader Trend: Experience Over Hype

The move by Welch and Lubner to join a clinical-stage company is indicative of a larger trend in the biopharmaceutical industry. As the science becomes more complex and the path to market more expensive, there is a premium on leadership that has successfully navigated the journey before. Experienced executives are increasingly being drawn to innovative smaller companies where their guidance can have a direct and substantial impact.

For Kinaset, attracting this level of talent is a powerful validation of its science and strategy. It suggests that leaders with a keen eye for value see a compelling opportunity in frevecitinib and the team developing it. In an industry often driven by hype, Kinaset's focus on shoring up its execution and governance capabilities is a grounded, informed strategy that prioritizes results over rhetoric.